Subscribe To
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Is netflix a buy?
Investors were delighted with Netflix's latest subscriber numbers. Management also added to Netflix's share-buyback capacity....
October 22, 2023, 9:45 am
Revolution medicines presents promising clinical activity and safety data from phase 1/1b trial of rmc-6236
Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) — Revolution Medicine...
October 22, 2023, 6:30 am
Bitcoin mining and ai meet in a new texas data center
It was a matter of time before Artificial Intelligence found an entrance ground to Bitcoin Mining. Applied Digital has brought this marriage to life a...
October 21, 2023, 5:44 pm
Studio city international: a pure play on macao's reopening and recovery
Macao's casinos have finally reopened after almost 3 years of lockdown, benefiting Studio city Internat...
October 21, 2023, 7:20 am
Xencor: a mid-stage clinical company with falling losses
Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li...
October 20, 2023, 11:02 pm
Pike/wayne association of realtors® joins mls grid; taps data delivery and standardization expertise
SALT LAKE CITY, Oct. 20, 2023 (GLOBE NEWSWIRE) — The Pike/Wayne Association of REALTORS announces that the organization’s Multiple Listing Service...
October 20, 2023, 5:30 pm
Why oracle stock was dropping today
JPMorgan said it will take time for Oracle to convert bookings into revenue. Demand for AI computing capacity ...
October 20, 2023, 2:00 pm
Us regulator approves tc energy's gas pipeline expansion in pacific northwest
The United States Federal Energy Regulatory Commission (FERC) on Thursday approved the expansion of TC Energy's Gas Transmission Northwest (GTN), know...
October 20, 2023, 10:15 am
Barclays: will loan growth have slowed and loan losses risen more in latest quarter?
Shares in Barclays PLC (LSE:BARC), which reports results on Tuesday 24 October, are pretty much exactly where they were a year ago, even though inter...
October 20, 2023, 9:19 am